ATTR Expanded Access Program (EAP) by Ionis

Status Approved for marketing

Clinical Trial Summary

The purpose of this program is to provide expanded access to Inotersen for up to 100 Patients with Hereditary Transthyretin Amyloidosis (hTTR).

Clinical Trial Description

The Program is intended to provided expanded access to Inotersen for eligible patients with hATTR who have limited or no available treatment options. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03400098
Study type	Expanded Access
Source	Ionis Pharmaceuticals, Inc.
Contact
Status	Approved for marketing
Phase

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05974644` - Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry
Recruiting	`NCT05879874` - Prospective Evaluation of NfL as a Biomarker in ATTRv
Recruiting	`NCT05489549` - Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Completed	`NCT01960348` - APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis	Phase 3
Active, not recruiting	`NCT03759379` - HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)	Phase 3
Completed	`NCT02319005` - ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)	Phase 3
Recruiting	`NCT05873868` - Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
Approved for marketing	`NCT02939820` - Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)